AJPH
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


American Journal of Public Health, Vol. 82, Issue 6 857-861, Copyright © 1992 by American Public Health Association

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Andrews, E B
Right arrow Articles by Schultz, M W
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Andrews, E B
Right arrow Articles by Schultz, M W
Postmarketing surveillance study of permethrin creme rinse.

E B Andrews, M C Joseph, M J Magenheim, H H Tilson, P A Doi and M W Schultz

Burroughs Wellcome Company, Research Triangle Park, NC 27709.

BACKGROUND. An observational, epidemiological study was undertaken to evaluate the safety of permethrin 1% creme rinse (Nix) for treatment of head lice infestations. METHODS. Thirty-seven local public health departments enrolled a total of 38,160 patients for 47,578 treatments with permethrin or other pediculicides from September 1, 1986, through January 31, 1988. Follow-up safety information was collected between 7 and 14 days following treatment via return visit or telephone contact. RESULTS. One hundred three adverse events were reported among 41,955 evaluable treatments. The rates of reported adverse events were 2.2 per 1000 treatments among permethrin treatments, 3.4 per 1000 treatments among lindane treatments, and 1.5 per 1000 treatments among other over-the-counter treatments. No serious, unexpected adverse events were detected in the 18,950 patients treated with permethrin. CONCLUSIONS. This study confirmed the safety profile of permethrin in conditions of general use, as seen in clinical trials. Postmarketing safety monitoring in public health departments of drugs used to treat public health conditions was shown to be feasible.




This article has been cited by other articles:


Home page
PediatricsHome page
L. K. Williams, A. Reichert, W. R. MacKenzie, A. W. Hightower, and P. A. Blake
Lice, Nits, and School Policy
Pediatrics, May 1, 2001; 107(5): 1011 - 1015.
[Abstract] [Full Text]


Home page
BMJHome page
R. H V. Stichele, E. M Dezeure, and M. G Bogaert
Systematic review of clinical efficacy of topical treatments for head lice
BMJ, September 2, 1995; 311(7005): 604 - 608.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1992 by the American Public Health Association